Cas:245653-51-4 4-[4-(1,1-DiMethylethyl)phenyl]-2,3-dihydro-2-Methyl-1H-inden-1-one manufacturer & supplier

We serve Chemical Name:4-[4-(1,1-DiMethylethyl)phenyl]-2,3-dihydro-2-Methyl-1H-inden-1-one CAS:245653-51-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-[4-(1,1-DiMethylethyl)phenyl]-2,3-dihydro-2-Methyl-1H-inden-1-one

Chemical Name:4-[4-(1,1-DiMethylethyl)phenyl]-2,3-dihydro-2-Methyl-1H-inden-1-one
CAS.NO:245653-51-4
Synonyms:4-[4-(1,1-DiMethylethyl)phenyl]-2,3-dihydro-2-Methyl-1H-inden-1-one
Molecular Formula:C20H22O
Molecular Weight:278.38808
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-[4-(1,1-DiMethylethyl)phenyl]-2,3-dihydro-2-Methyl-1H-inden-1-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-[4-(1,1-DiMethylethyl)phenyl]-2,3-dihydro-2-Methyl-1H-inden-1-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-[4-(1,1-DiMethylethyl)phenyl]-2,3-dihydro-2-Methyl-1H-inden-1-one Use and application,4-[4-(1,1-DiMethylethyl)phenyl]-2,3-dihydro-2-Methyl-1H-inden-1-one technical grade,usp/ep/jp grade.


Related News: Capturing multiple aspects of improvement increases confidence that anifrolumab may be an important option for patients.” 4-(1-(4-methoxyphenyl)ethyl)morpholine manufacturers After speaking to iRhythm on Tuesday, J.P. Morgan analysts wrote we shouldn’t expect an update on reimbursement before the release of the Physician Fee Schedule proposed rule in July/August. (+-)-2-(γ-(3-Hydroxy-propylamino)-isobutyl)-benzdioxan-(1,4) suppliers The results provided a formulation amenable to two dosage strengths by applying a proportional dosing weight method.” The product is currently in late-stage development with the New Drug Application filing expected in late 2021. Peptide, (Lys-Trp-Xaa-Xaa-Xaa-Phe) vendor & factory.